Search / Trial NCT06617104

Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Sep 26, 2024

Apply for Trial

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Description

Data collection was conducted at a medical center in northern Taiwan. Sample size estimation was performed using G\*Power 3.1. A total of 50 patients with schizophrenia were assigned to the disease group, and 50 healthy individuals were assigned to the control group, with a total of 100 participants expected. Data collection included: personal demographic questionnaire, body constitution questionnaire (BCQ), WHOQOL-BREF (Taiwan version) for quality of life, brief psychiatric rating scale (BPRS), heart rate variability (HRV), meridian energy

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Disease group：
  • * Diagnosed with schizophrenia by a physician (ICD-10 code F20, such as F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, or F20.9), with stable condition, and has not had any changes in medication dosage or admission to a psychiatric acute care unit in the past 3 months.
  • * Aged between 18 and 65 years.
  • * Able to understand, speak, read, and write Mandarin or Taiwanese.
  • 2. Control group：
  • * No history of chronic illness and no acute symptoms within the past month.
  • * Aged between 18 and 65 years.
  • * Able to understand, speak, read, and write Mandarin or Taiwanese.
  • Exclusion Criteria:
  • 1. Disease group：
  • * Individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues.
  • * Individuals who have used medications affecting the autonomic nervous system within the past month, such as mood stabilizers, antidepressants, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics.
  • * Individuals with metallic implants that could affect heart rate variability.
  • * Individuals with involuntary and uncontrollable body tremors.
  • * Women currently menstruating.
  • * Pregnant women.
  • 2. Control group：
  • * Individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues.
  • * Individuals who have used medications affecting the autonomic nervous system within the past month, such as psychiatric medications, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics .
  • * Individuals with metallic implants that could affect heart rate variability.
  • * Individuals with involuntary and uncontrollable body tremors.
  • * Women currently menstruating.
  • * Pregnant women.

About National Taiwan University Hospital

National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.

Locations

Taipei, , Taiwan

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0